EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial

M R Seefat, C A M Stege, B I Lissenberg-Witte, M D Levin, G J Timmers, M Hoogendoorn, P F Ypma, S K Klein, G A Velders, M Westerman, L Strobbe, N Durdu-Rayman und 16 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114153 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024. Verfasst von M R Seefat und 27 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlandsī. Hauptthemen laut MEDLINE: Multiple Myeloma, Quality of Life, Bortezomib, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen Pharmaceutica, KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Frailty in newly-diagnosed multiple myeloma (NDMM) patients is associated with treatment-related toxicity, which negatively affects health-related quality of life (HRQoL). Currently, data on changes in HRQoL of frail and intermediate-fit MM patients during active treatment and post-treatment follow-up are absent. METHODS: The HOVON123 study (NTR4244) was a phase II trial in which NDMM patients ≥ 75 years were treated with nine dose-adjusted cycles of Melphalan-Prednisone-Bortezomib (MPV). Two HRQoL instruments (EORTC QLQ-C30 and -MY20) were obtained before start of treatment, after 3 and 9 months of treatment and 6 and 12 months after treatment for patients who did not yet start second-line treatment. HRQoL changes and/or differences in frail and intermediate-fit patients (IMWG frailty score) were reported only when both statistically significant (p MID). RESULTS: 137 frail and 71 intermediate-fit patients were included in the analysis. Compliance was high and comparable in both groups. At baseline, frail patients reported lower global health status, lower physical functioning scores and more fatigue and pain compared to intermediate-fit patients. Both groups improved in global health status and future perspective; polyneuropathy complaints worsened over time. Frail patients improved over time in physical functioning, fatigue and pain. Improvement in global health status occurred earlier than in intermediate-fit patients. CONCLUSION: HRQoL improved during anti-myeloma treatment in both intermediate-fit and frail MM patients. In frail patients, improvement occurred faster and, in more domains, which was retained during follow-up. This implies that physicians should not withhold safe and effective therapies from frail patients in fear of HRQoL deterioration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaQuality of LifeBortezomibAntineoplastic Combined Chemotherapy ProtocolsFrailtyHumansAgedMaleFemaleProspective StudiesAged, 80 and overMelphalanPrednisoneFrail Elderly

Stichwörter der Autor:innen

Frailty scoreIMWGMultiple myelomaNewly diagnosedQuality of Life

Substanzen

BortezomibMelphalanPrednisone

Autor:innen und Institutionen

  • Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlandsī.
  • Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlandsī.
  • Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
  • Internal Medicine, Amstelland Hospital, Amstelveen, the Netherlands.
  • Hematology, Medical Center Leeuwarden, Leeuwarden, the Netherlands.

Förderung

  • Janssen Pharmaceutica
  • KWF Kankerbestrijding

Zitieren

APA

Seefat, M. R., Stege, C. A. M., Lissenberg-Witte, B. I., Levin, M. D., Timmers, G. J., Hoogendoorn, M., Ypma, P. F., Klein, S. K., Velders, G. A., Westerman, M., Strobbe, L., Durdu-Rayman, N., Davidis-van Schoonhoven, M. A., van Kampen, R. J. W., Dijk, A. C., Koster, A., Silbermann, M. H., van der Spek, E., Beeker, A., …, & Zweegman, S. (2024). Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114153

Vancouver

Seefat MR, Stege CAM, Lissenberg-Witte BI, Levin MD, Timmers GJ, Hoogendoorn M, et al. Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114153

BibTeX
@article{Seefat2024,
  author = {Seefat, M R and Stege, C A M and Lissenberg-Witte, B I and Levin, M D and Timmers, G J and Hoogendoorn, M and Ypma, P F and Klein, S K and Velders, G A and Westerman, M and Strobbe, L and Durdu-Rayman, N and Davidis-van Schoonhoven, M A and van Kampen, R J W and Dijk, A C and Koster, A and Silbermann, M H and van der Spek, E and Beeker, A and Erjavec, Z and de Graauw, N C H P and Leys, M B L and Sonneveld, P and van de Donk, N W C J and Nasserinejad, K and Blommestein, H M and Cucchi, D G J and Zweegman, S},
  title = {Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114153}
}
Kostenlos starten →